Table 2.
Comparison of combination chemotherapy agents in platinum-sensitive recurrent disease
| Study | N | Regimen | Median PFS | Median OS |
|---|---|---|---|---|
| Pujade-Lauraine et al19 | 467 | Carboplatin + liposomal doxorubicin | 11.3 months | Not reached |
| HR 0.821; 95% Ci 0.72–0.94 | ||||
| 509 | Carboplatin + paclitaxel | 9.4 months | ||
| HECTOR22 | Carboplatin + topotecan | Study completion estimated for | ||
| September 2013 | ||||
| NCT00437307 | Carboplatin and other drug | |||
| Katsumata et al21 | Carboplatin + taxol weekly | 28 months | 72.1% at 3 years | |
| JGOG 3016 | Carboplatin + taxol | 17.2 months | 65.1% | |
| q3wk | P = 0.0015 | P = 0.03 |
Abbreviations: CI, confidence interval; HR, hazard ratio; N, number; OS, overall survival; PFS, progression-free survival.